N2B-patch SIGNED
Nose to Brain Delivery of antibodies via the Olfactory Region for the Treatment of Multiple Sclerosis Using Novel Multi-functional Biomaterials Combined with a Medical Device
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0N2B-patch project word cloud
Explore the words cloud of the N2B-patch project. It provides you a very rough idea of what is the project "N2B-patch" about.
Project "N2B-patch" data sheet
The following table provides information about the project.
| Coordinator |
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Organization address contact info |
| Coordinator Country | Germany [DE] |
| Project website | https://n2b-patch.eu/ |
| Total cost | 6˙472˙998 € |
| EC max contribution | 5˙325˙498 € (82%) |
| Programme |
1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials) |
| Code Call | H2020-NMBP-2016-two-stage |
| Funding Scheme | RIA |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-01-01 to 2020-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. | DE (MUNCHEN) | coordinator | 783˙095.00 |
| 2 | HOCHSCHULE BIBERACH | DE (BIBERACH) | participant | 1˙102˙398.00 |
| 3 | BEITER GMBH GO KG | DE (SIGMARINGENDORF) | participant | 728˙125.00 |
| 4 | JENSONR+ LIMITED | UK (BARNSTAPLE DEVON) | participant | 611˙700.00 |
| 5 | MJR PHARMJET GMBH | DE (UBERHERRM) | participant | 559˙137.00 |
| 6 | ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS | EL (THERMI THESSALONIKI) | participant | 495˙000.00 |
| 7 | CONTIPRO AS | CZ (DOLNI DOBROUC) | participant | 400˙000.00 |
| 8 | LGI CONSULTING | FR (PARIS) | participant | 291˙250.00 |
| 9 | LABORATORIO EUROPEO DI SPETTROSCOPIE NON LINEARI | IT (Sesto-Fiorentino (FI)) | participant | 227˙500.00 |
| 10 | THE EUROPEAN MULTIPLE SCLEROSIS PLATFORM AISBL | BE (BRUXELLES) | participant | 127˙292.00 |
| 11 | NOVAGO THERAPEUTICS AG | CH (SCHLIEREN) | participant | 0.00 |
| 12 | UNIVERSITAET BERN | CH (BERN) | participant | 0.00 |
Map
Project objective
The overall aim of N2B-patch is the development of a new innovative N2B drug delivery technology based on the synthesis of a biomaterial-based innovative galenic formulation that will be applied with the aid of a novel medical device equipped with a container closure system (CCS) as a hydrogel patch to the nasal olfactory region for the chronic treatment of MS. The galenic formulation will consist of drug loaded biodegradable polymer particles (e.g., chitosan, polylactic-co-glycolic acid, PLGA) embedded into a biodegradable hydrogel matrix (e.g., hyaluronic acid (HA)-based) to be deposited as a patch onto the olfactory region. A pH-sensitive, mucoadhesive particle coating (e.g., chitosan, chitosan derivatives) will ensure an environment-specific adhesion to the olfactory epithelium. This novel technology will largely enhance the controlled and sustainable delivery of drugs and increase the drug bioavailabilty to the CNS. NogoA antagonist NG-101 will be used as an active pharmaceutical ingredient (API). Proof of concept studies and initial clinical data have proven the enormous potential of blocking NogoA for spinal cord remyelation and axonal integrity. However, monoclonal antibodies (mAb) like NG-101, do not sufficiently cross the BBB. The sustainable and controlled release of NG-101 to the CNS will be achieved via the transport of embedded polymer particles to the olfactory epithelium, the subsequent release of API and permeation through the olfactory region, the only part of the nasal epithelium which is in direct contact with the brain. The direct transport route from the nasal cavity to the brain, bypassing the BBB, offers an exciting mode of central nervous system (CNS) drug delivery not only for demyelinating disorders but also for other CNS indications, e.g., stroke, neurodegenerative diseases or tumours. The proposed new innovative N2B drug delivery platform is a practical, safe, and minimally invasive technology. It will be exploited for NG-101 and has the potential to be implemented with other APIs with a low CNS bioavailability.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Simone Ladel, Patrick Schlossbauer, Johannes Flamm, Harald Luksch, Boris Mizaikoff, Katharina Schindowski Improved In Vitro Model for Intranasal Mucosal Drug Delivery: Primary Olfactory and Respiratory Epithelial Cells Compared with the Permanent Nasal Cell Line RPMI 2650 published pages: 367, ISSN: 1999-4923, DOI: 10.3390/pharmaceutics11080367 |
Pharmaceutics 11/8 | 2020-04-14 |
| 2018 |
Aleck H. Alexopoulos, Costas Kiparissides A Computational Model for the Analysis of Spreading of Viscoelastic Droplets over Flat Surfaces published pages: 78, ISSN: 2311-5521, DOI: 10.3390/fluids3040078 |
Fluids 3/4 | 2020-04-14 |
| 2018 |
Simone Ladel, Johannes Flamm, Arghavan Soleimani Zadeh, Dorothea Filzwieser, Julia-Christina Walter, Patrick Schlossbauer, Ralf Kinscherf, Katharina Lischka, Harald Luksch, Katharina Schindowski Allogenic Fc Domain-Facilitated Uptake of IgG in Nasal Lamina Propria: Friend or Foe for Intranasal CNS Delivery? published pages: 107, ISSN: 1999-4923, DOI: 10.3390/pharmaceutics10030107 |
Pharmaceutics 10/3 | 2020-04-14 |
| 2018 |
Bourganis, Vassilis; Kammona, Olga; Alexopoulos, Aleck; Kiparissides, Costas Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics published pages: 337-362, ISSN: 0939-6411, DOI: 10.5281/zenodo.1256646 |
European Journal of Pharmaceutics and Biopharmaceutics 128 | 2020-04-14 |
| 2018 |
Gruber-Traub C, Ullrich J. »N2B-Patch« – Nose-to-Brain Delivery of an Active Pharmaceutical Ingredient via the Olfactory Region published pages: , ISSN: 2637-4706, DOI: |
Drug Designing & Intellectual Properties International Journal | 2020-04-14 |
| 2018 |
Stella Gänger, Katharina Schindowski Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa published pages: 116, ISSN: 1999-4923, DOI: 10.3390/pharmaceutics10030116 |
Pharmaceutics 10/3 | 2020-04-14 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "N2B-PATCH" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "N2B-PATCH" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.2.1.3.)
SMARTFAN (2018)
Smart by Design and Intelligent by Architecture for turbine blade fan and structural components systems
Read MoreReSHEALience (2018)
Rethinking coastal defence and Green-Energy Service infrastructures through enHancEd-durAbiLIty high-performance fiber reinforced cement-based materials.
Read MoreSYNAMERA (2015)
Synergies in Nanotechnologies, Materials and Production in the European Research Area
Read More